A new compound that inhibits the activity of alertness-promoting brain peptides called orexins shows promise as a sleeping pill, according to tests in people and animals.
Men who took the drug fell asleep more quickly than did men who took a placebo, neurobiologist François Jenck of Actelion Pharmaceuticals in Allschwil, Switzerland, and his collaborators report in the February Nature Medicine.
Larger doses of the drug act faster and seem to have a stronger effect than do smaller doses, the researchers found. They previously observed similar effects in both dogs and rats.
The duration of drug-induced somnolence also depends on dose. The highest dose used in people caused drowsiness that lasted about 10 hours, the researchers report.
The drug, now known as ACT-078573, harnesses the 8-year-old discovery that insufficient orexin activity in the brain causes narcolepsy, a disorder of excessive sleepiness (SN: 8/14/99, p. 100: http://www.sciencenews.org/pages/sn_arc99/8_14_99/fob1.htm). Researchers have since theorized that an orexin-blocking drug might overcome insomnia.
Narcoleptic people experience sudden bouts of muscle weakness, called cataplexy. Jenck's team found no signs of cataplexy as a side effect of the drug.
Research and Development
Actelion Pharmaceuticals Ltd.
Harder, B. 2004. Narcolepsy science reawakens. Science News 165(June 19):394-395. Available to subscribers at [Go to].
Scammell, T.E., and C.B. Saper. Orexins: looking forward to sleep, back at addiction. Nature Medicine 13(February):126-128. Summary available at [Go to].
Travis, J. 2000. Brain-cell loss found in narcolepsy. Science News 158(Sept. 2):148. Available at [Go to].
______. 1999. Animal genes illuminate human sleep. Science News 156(Aug. 14):100. Available at [Go to].